The closer we get to 2028, the more likely it is that the U.S. may settle for short-term solutions that do not meaningfully ...

On August 6, 2025, the U.S. Court of Appeals for the Second Circuit issued an opinion allowing a case challenging drug pricing changes to proceed. The case, an antitrust action brought by health ...

The 340B Drug Pricing Program (“340B Program”) space continues to be a hive of activity. While 340B stakeholders continue to litigate ongoing manufacturer contract pharmacy restrictions, states ...

SPRINGFIELD, Ill. (WCIA) — Faith and community leaders gathered in Springfield on Wednesday to call for increased oversight ...

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program ...

Five companies account for 76.1% of the 340B contract pharmacy market, according to Drug Channels. Since Congress established the 340B program in 1992, the program has expanded to include 32,069 ...

If New York legislators have questions about the efficacy of the 340B Drug Pricing Program, they should look closely at a ...

A federal court recently blocked the Trump administration from moving forward with a proposed pilot program that could have ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...

The 340B Drug Pricing Program was originally constructed so safety-net health care facilities could stretch scarce resources in caring for low-income patients. However, the program has experienced ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...